|
| | Publication Year | Title | Author(s) |
| 1 | Oct-2019 | Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. | Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; Cebon, Jonathan S ; Ferrucci, Pier Francesco; Aglietta, Massimo; Neyns, Bart; Chiarion-Sileni, Vanna; Lindsay, Colin R; Del Vecchio, Michele; Linardou, Helen; Merelli, Barbara; Tonini, Giuseppe; Atkinson, Victoria; Freivogel, Klaus; Stein, Dara; Dalland, Lindi; Lau, Mike; Legenne, Philippe; Queirolo, Paola; Millward, Michael |
| 2 | 5-Sep-2019 | Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. | Gunjur, Ashray ; Klein, Oliver ; Kee, Damien ; Cebon, Jonathan S |
| 3 | Aug-2019 | A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. | Arulananda, Surein; Parakh, Sagun ; Palmer, Jodie ; Goodwin, Mark D ; Andrews, Miles C; Cebon, Jonathan S |
| 4 | May-2019 | Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. | Gray, Elin S; Witkowski, Tom ; Pereira, Michelle; Calapre, Leslie; Herron, Karl; Irwin, Darryl; Chapman, Brett; Khattak, Muhammad A; Raleigh, Jeanette; Hatzimihalis, Athena; Cebon, Jonathan S ; Sandhu, Shahneen; McArthur, Grant A; Millward, Michael; Ziman, Melanie; Dobrovic, Alexander ; Wong, Stephen Q |
| 5 | 24-Apr-2019 | BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. | Lee, Erinna F; Harris, Tiffany J ; Tran, Sharon; Evangelista, Marco; Arulananda, Surein; John, Thomas ; Ramnac, Celeste; Hobbs, Chloe; Zhu, Haoran; Gunasingh, Gency; Segal, David; Behren, Andreas; Cebon, Jonathan S ; Dobrovic, Alexander ; Mariadason, John M ; Strasser, Andreas; Rohrbeck, Leona; Haass, Nikolas K; Herold, Marco J; Fairlie, W Douglas |
| 6 | Feb-2019 | Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. | Parakh, Sagun ; Randhawa, Manreet; Nguyen, Bella; Warburton, Lydia; Hussain, Mohammad Akhtar; Cebon, Jonathan S ; Millward, Michael; Yip, Desmond; Ali, Sayed |
| 27 | Dec-2018 | Perspective: cancer vaccines in the era of immune checkpoint blockade. | Cebon, Jonathan S |
| 28 | 22-Nov-2018 | Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. | Liew, David F L ; Leung, Jessica L Y ; Liu, Bonnia ; Cebon, Jonathan S ; Frauman, Albert G ; Buchanan, Russell R C |
| 9 | 12-Nov-2018 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. | Mitchell, Emma L; Lau, Peter Kar Han; Khoo, Chloe; Liew, David F; Leung, Jessica; Liu, Bonnia ; Rischin, Adam; Frauman, Albert G ; Kee, Damien ; Smith, Kortnye; Brady, Benjamin; Rischin, Danny; Gibson, Andrew; Mileshkin, Linda; Klein, Oliver ; Weickhardt, Andrew; Arulananda, Surein; Shackleton, Mark; McArthur, Grant; Östör, Andrew; Cebon, Jonathan S ; Solomon, Benjamin; Buchanan, Russell R C ; Wicks, Ian P; Lo, Serigne; Hicks, Rodney J; Sandhu, Shahneen |
| 10 | 6-Nov-2018 | Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. | Bethune, Michael T; Li, Xiao-Hua; Yu, Jiaji; McLaughlin, Jami; Cheng, Donghui; Mathis, Colleen; Moreno, Blanca Homet; Woods, Katherine; Knights, Ashley J; Garcia-Diaz, Angel; Wong, Stephanie; Hu-Lieskovan, Siwen; Puig-Saus, Cristina; Cebon, Jonathan S ; Ribas, Antoni; Yang, Lili; Witte, Owen N; Baltimore, David |
| 11 | Nov-2018 | Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. | Kanatsios, Stefanos; Melanoma Project, Melbourne; Li Wai Suen, Connie S N; Cebon, Jonathan S ; Gyorki, David E |
| 12 | 24-Jul-2018 | Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. | Halse, H; Colebatch, A J; Petrone, P; Henderson, M A; Mills, J K; Snow, H; Westwood, J A; Sandhu, S; Raleigh, J M; Behren, Andreas; Cebon, Jonathan S ; Darcy, P K; Kershaw, M H; McArthur, G A; Gyorki, D E; Neeson, P J |
| 13 | Apr-2018 | Characterising the phenotypic evolution of circulating tumour cells during treatment. | Tsao, Simon Chang-Hao; Wang, Jing; Wang, Yuling; Behren, Andreas; Cebon, Jonathan S ; Trau, Matt |
| 14 | 2018 | Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. | Parakh, Sagun ; Cebon, Jonathan S ; Klein, Oliver |
| 15 | 2018 | Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. | Chan, Kok Fei; Gully, Benjamin S; Gras, Stephanie; Beringer, Dennis X; Kjer-Nielsen, Lars; Cebon, Jonathan S ; McCluskey, James; Chen, Weisan; Rossjohn, Jamie |
| 16 | 2018 | Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of IntralesionalBacillus Calmette-Guérinfollowed by Ipilimumab in Patients with Advanced Metastatic Melanoma. | Da Gama Duarte, Jessica; Parakh, Sagun ; Andrews, Miles C; Woods, Katherine; Pasam, Anupama; Tutuka, Candani; Ostrouska, Simone; Blackburn, Jonathan M; Behren, Andreas; Cebon, Jonathan S |
| 17 | 1-Dec-2017 | Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. | Sznol, Mario; Ferrucci, Pier Francesco; Hogg, David; Atkins, Michael B; Wolter, Pascal; Guidoboni, Massimo; Lebbé, Celeste; Kirkwood, John M; Schachter, Jacob; Daniels, Gregory A; Hassel, Jessica; Cebon, Jonathan S ; Gerritsen, Winald; Atkinson, Victoria; Thomas, Luc; McCaffrey, John; Power, Derek; Walker, Dana; Bhore, Rafia; Jiang, Joel; Hodi, F Stephen; Wolchok, Jedd D |
| 18 | Nov-2017 | Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ. | Vella, Laura J; Behren, Andreas; Coleman, Bradley; Greening, David W; Hill, Andrew F; Cebon, Jonathan S |
| 19 | Nov-2017 | Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma | Petrella, Teresa M; Robert, Caroline; Richtig, Erika; Miller, Wilson H Jr; Masucci, Giuseppe V; Walpole, Euan; Lebbe, Celeste; Steven, Neil; Middleton, Mark R; Hille, Darcy; Zhou, Wei; Ibrahim, Nageatte; Cebon, Jonathan S |
| 20 | 5-Oct-2017 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. | Wolchok, Jedd D; Chiarion-Sileni, Vanna; Gonzalez, Rene; Rutkowski, Piotr; Grob, Jean-Jacques; Cowey, C Lance; Lao, Christopher D; Wagstaff, John; Schadendorf, Dirk; Ferrucci, Pier F; Smylie, Michael; Dummer, Reinhard; Hill, Andrew; Hogg, David; Haanen, John; Carlino, Matteo S; Bechter, Oliver; Maio, Michele; Marquez-Rodas, Ivan; Guidoboni, Massimo; McArthur, Grant; Lebbé, Celeste; Ascierto, Paolo A; Long, Georgina V; Cebon, Jonathan S ; Sosman, Jeffrey; Postow, Michael A; Callahan, Margaret K; Walker, Dana; Rollin, Linda; Bhore, Rafia; Hodi, F Stephen; Larkin, James |
Loading...
2
0
20
0
false
0000-0002-3898-950x